Inspire Medical Systems, Inc. Announces Additional 17.7 Million Covered Lives with Seven New Coverage Policies

Download as PDF

Includes Positive Policy from Health Care Service Corporation, the Largest Customer-Owned
Health Insurer in the U.S. and Fourth Largest Overall

MINNEAPOLIS, MN – August 15, 2019 – Inspire Medical Systems, Inc. (NYSE: INSP) (the “Company or
“Inspire”), a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today
the addition of seven new positive coverage policies, including five Blue Cross Blue Shield Association
(“BCBSA”) plans, adding approximately 17.7 million covered lives to the growing slate of positive
coverage policies of Inspire therapy.

Details of the seven new positive coverage policies include:

  • Health Care Service Corporation (“HCSC”), an Independent Licensee of the BCBSA, covers
    approximately 14.7 million lives, and becomes effective September 1, 2019. HCSC is the largest
    customer-owned health insurer in the United States and fourth largest overall, operating through Blue
    Cross and Blue Shield Plans in Texas, Illinois, Montana, New Mexico, and Oklahoma;
  • Arkansas Blue Cross and Blue Shield covers approximately 665,000 members and became effective
    August 1, 2019;
  • Priority Health covers approximately 625,000 members and became effective July 1, 2019;
  • Blue Cross Blue Shield of Nebraska covers approximately 580,000 members and became effective
    June 5, 2019;
  • Blue Cross Blue Shield of Arizona covers approximately 390,000 members and became effective July
    31, 2019;
  • Blue Cross Blue Shield of North Dakota covers approximately 355,000 members and becomes
    effective September 1, 2019; and
  • Capital District Physicians’ Health Plan covers approximately 360,000 members and became
    effective July 1, 2019.

“We are very pleased to receive these positive coverage decisions. As health plans continue to update
their coverage policies to include Inspire therapy, an increasing number of patients and physicians will
have access to our innovative therapy,” said Tim Herbert, President and Chief Executive Officer of Inspire
Medical Systems. “We now have 41 coverage policies, including 26 coverage policies issued by BCBSA
plans, representing a total of approximately 142 million members. We remain focused on continuing this
momentum with all payers in the United States.”

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary
Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and
effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking
statements, including, without limitation, statements regarding future positive insurance coverage of
Inspire therapy and improvements in market access. In some cases, you can identify forward-looking
statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,”
“outlook,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’
‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking
statements contain these words.

These forward-looking statements are based on management’s current expectations and involve known
and unknown risks and uncertainties that may cause our actual results, performance or achievements to
be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the
annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the
U.S.; future results of operations, financial position, research and development costs, capital
requirements and our needs for additional financing; commercial success and market acceptance of our
Inspire therapy; our ability to achieve and maintain adequate levels of coverage or reimbursement for our
Inspire system or any future products we may seek to commercialize; competitive companies and
technologies in our industry; our ability to enhance our Inspire system, expand our indications and
develop and commercialize additional products; our business model and strategic plans for our products,
technologies and business, including our implementation thereof; our ability to accurately forecast
customer demand for our Inspire system and manage our inventory; our dependence on third-party
suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our
ability to expand, manage and maintain our direct sales and marketing organization, and to market and
sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our
ability to manage our growth; our ability to increase the number of active medical centers implanting
Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel;
risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to
or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire
therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or
other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including
healthcare reform measures in the U.S. and international markets; the timing or likelihood of regulatory
filings and approvals; risks related to our debt and capital structure; our ability to establish and maintain
intellectual property protection for our Inspire therapy and system or avoid claims of infringement; tax
risks; risks that we may be deemed an investment company under the Investment Company Act of 1940;
regulatory risks; the volatility of the trading price of our common stock; and our expectations about market
trends. Other important factors that could cause actual results, performance or achievements to differ
materially from those contemplated in this presentation can be found under the captions “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations“ in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as such factors may be
updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at
www.sec.gov. These and other important factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this presentation. Any such forward-looking
statements represent management’s estimates as of the date of this presentation. While we may elect to
update such forward-looking statements at some point in the future, unless required by applicable law, we
disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should
not assume that our silence over time means that actual events are bearing out as expressed or implied
in such forward-looking statements. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this press release.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989